drugset / Trial / NCT05290493
NB-001 in Children and Adolescents With 22q11 Deletion Syndrome
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a Phase 2, randomized, placebo-controlled crossover trial to assess the safety and efficacy of NB-001 in children and adolescents with 22q11DS that manifest commonly associated neuropsychiatric symptoms.
Timeline
- Start
- 2022-02-10
- Primary completion
- 2023-06-01
- Completion
- 2023-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NB-001 | Other / unclassified | 200 mg | Oral |